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Abstract
Background:  Donepezil improves cognitive functions in AD patients. Effects on the brain
metabolites N-acetyl-L-aspartate, choline and myo-inositol levels have been reported in clinical
studies using this drug. The APP/PS1 mouse coexpresses the mutated forms of human β-amyloid
precursor protein (APP) and mutated human presenilin 1 (PS1). Consequently, the APP/PS1 mouse
model reflects important features of the neurochemical profile in humans. In vivo magnetic
resonance spectroscopy (1H-MRS) was performed in fronto-parietal cortex and hippocampus (ctx/
hipp) and in striatum (str). Metabolites were quantified using the LCModel and the final analysis was
done using multivariate data analysis. The aim of this study was to investigate if multivariate data
analysis could detect changes in the pattern of the metabolic profile after donepezil treatment.
Results: Significant differences were observed in the metabolic pattern of APP/PS1 mice in both
str and ctx/hipp before and after donepezil treatment using multivariate data analysis, evidencing a
significant treatment effect. A treatment effect was also seen in wild type (wt) mice in str. A
significant decrease in the metabolic ratio taurine/creatine (Tau/tCr) was related to donepezil
treatment (p < 0.05) in APP/PS1 mice in both brain regions. Furthermore, a significant influence on
the choline/creatine (tCho/tCr) level was observed in treated APP/PS1 mice compared to
untreated in str (p = 0.011). Finally, there was an increase in glutamate/creatine (Glu/tCr) in str in
wt mice treated with donepezil.
Conclusion: Multivariate data analysis can detect changes in the metabolic profile in APP/PS1 mice
after donepezil treatment. Effects on several metabolites that are measurable in vivo using MR
spectroscopy were observed. Changes in Tau/tCr and tCho/tCr could possibly be related to
changed cholinergic activity caused by donepezil treatment.
Background
Proton magnetic resonance spectroscopy (1H-MRS) pro-
vides useful information on the neurochemical profile in
different neurodegenerative diseases [1,2]. It is a non-
invasive method which allows the investigation of the
chemical profile of defined target volumes in subjects in
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vivo. Examples of measurable metabolites are N-acety-
laspartate (NAA) a marker for neuronal density and/or
function, myo-inositol (m-Ins) a marker for astrogliosis
and/or osmotic stress and choline (Cho) a marker for cell
membrane turnover and degradation [3]. Brain metabo-
lites are sensitive to pathological processes in neurodegen-
erative disorders such as Alzheimer's disease (AD) [2].
AD is one of the most common forms of neurodegenera-
tive disorders [4]. The clinical symptoms of AD include
progressive memory impairment, disordered cognitive
functions, altered behaviour including paranoia, delu-
sions, loss of social appropriateness and decline in lan-
guage functions. The majority of the prevalent AD cases
are sporadic. The small percentage of remaining AD cases
are familial and connected to specific gene mutations [4].
There are few approved treatment options for AD. One of
them is the administration of acetylcholine-esterase
(AchE) inhibitors, like donepezil which enhances the life
of the neurotransmitter acetylcholine in the synapse and
thus increases the cholinergic neurotransmission [5].
Symptomatically, donepezil improves cognitive functions
in AD patients[6,7]. Using Magnetic Resonance spectros-
copy (MRS) in patients, brain metabolites and neuro-
transmitters can be non-invasively measured and effects
on brain NAA levels caused by donepezil have been
reported [7,8]. Moreover, effects on m-Ins and Cho in hip-
pocampus of AD patients treated with donepezil have
been observed [9].
Different animal models that express one or more mutant
proteins associated with AD allow us to study different
features of AD [10-14]. While some models may express
different levels of β-amyloid [15,16], other models mod-
ulate the production of tangles [17,18]. We investigated
the neurochemical profile of the double transgenic (tg)
APP/PS1 mouse [19,20] during maturation and ageing in
a previous study [21]. As a continuation of this, we have
investigated the effects of donepezil treatment in the same
mouse model. The APP/PS1 mouse coexpresses the
mutated forms of human β-amyloid precursor protein
(APP) and mutated human presenilin 1 (PS1) and thus
reflects important features of the neurochemical profile in
humans [22].
The aim of this study was to investigate the possibility of
monitoring early donepezil treatment effects in young
APP/PS1 mice with the combination of multivariate data
analysis and MRS. By doing so we wanted to observe
changes in the metabolic pattern as well as in individual
metabolites. We did not expect significant changes in the
levels of NAA and m-Ins as previously reported in humans
treated with donepezil. We based this on the fact that
these metabolites are not altered in the APP/PS1 mice
model until later in their development. Our hypothesis
was based on the multivariate model looking at the
underlying metabolic pattern rather than individual
metabolites. However, we believed the levels of choline
were most likely to be altered, since choline is a precursor
of acetylcholine and donepezil is an inhibitor of acetyl-
choline-esterase.
Results
Magnetic resonance spectroscopy (1H-MRS)
1H-MRS was used to monitor differences in metabolite
contents in vivo before and after donepezil treatment in
APP/PS1 mice. Also wt mice were investigated before and
after treatment. Two different volumes of interest (VOI)
were used in this study. The first one included parietal cor-
tex and hippocampus (10.24 mm3) and the second VOI
was placed in striatum (20 mm3). Fig. 1A (ctx/hipp) and
1B (str) demonstrates the placement of the two different
volumes of interest. A representative spectrum from ctx/
hipp of a wt mouse is shown in Fig. 1C and a representa-
tive spectrum from str is shown in Fig. 1D. Six different
variables (metabolite ratios) were quantified using the
software LCModel. These were tNAA/tCr, tCho/tCr, Tau/
tCr, m-Ins/tCr, Glu/tCr and Gln/tCr. Mean metabolic
ratios for all groups are shown in table 1.
Donepezil treatment effects on cortex/hippocampus 
depicted by multivariate data analysis
Multivariate data analysis was used to compare differ-
ences between mice before and after treatment. First we
compared spectra from ctx/hipp in APP/PS1 mice. Fig. 2A
shows a scatter plot of the PLS-DA group comparison
between APP/PS1 mice before and after treatment. A sig-
nificant separation (Q2 = 0.17) between the groups can be
observed. The first principle component (comp 1)
describes 49% of the variance of the original data. Leave-
one-out cross validation predicted 6/6 treated animals
and 5/6 untreated animals correctly (specificity = 100%;
sensitivity = 83%). There were no effects on the brain
metabolites in the non-treated APP/PS1 mice. Moreover,
no effect was observed on the metabolites in ctx/hipp in
donepezil or untreated wt mice (not shown).
Donepezil treatment effects on striatum depicted by 
multivariate data analysis
We then investigated spectra from str in APP/PS1 and wt
mice before and after treatment. There is a clear separation
between APP/PS1 animals before and after treatment with
donepezil (Fig. 3A.). There is one significant (Q2 = 0.39)
component that explains 75% of the variance of the orig-
inal data. Leave-one-out cross validation predicted 5/5
treated animals and 5/5 untreated animals correctly (spe-
cificity = 100%; sensitivity = 100%). Interestingly, we also
noted a separation between the spectra targeted in str of
untreated APP/PS1 mice (Fig. 4A). The first principle com-BMC Neuroscience 2009, 10:33 http://www.biomedcentral.com/1471-2202/10/33
Page 3 of 14
(page number not for citation purposes)
ponent (Q2 = 0.29) explains 58% of the variance of the
original data. Leave-one-out cross validation predicted 4/
5 treated animals and 4/5 untreated animals correctly
(specificity = 80%; sensitivity = 80%).
A treatment effect of donepezil was also observed in str for
wt mice (Fig. 5A). One significant component is seen (Q2
= 0.24) to explain 38% of the variance of the original data
and leave-one-out cross validation predicted 9/10 treated
animals and 8/10 untreated animals correctly (specificity
= 90%; sensitivity = 80%). No effect in str of wt animals
receiving saline injections was observed (not shown).
Metabolite ratios of importance for separation between 
groups
PLS-DA modelling pinpoints metabolite ratios which are
responsible for the separation between groups. Metabolite
ratios with a variable of importance (VIP) value larger
than one are over average responsible for the differences.
Hence, it can be seen that the most important metabolite
ratios for the separation of APP/PS1 mice before and after
donepezil treatment were Tau/tCr and Gln/tCr for meas-
urements in ctx/hipp (Fig. 2B) and Tau/tCr, tCho/tCr, m-
Ins/tCr for measurement in str (Fig. 3B). Interestingly,
there were also differences in the metabolic fingerprint in
untreated APP/PS1 mice in str. This might indicate
changes caused by disease progress. The metabolite ratios
that were responsible for these differences were tCho/tCr
and tNAA/tCr (Fig. 4B). Moreover, metabolite ratios of
importance for the separation for treated wt mice in str
(Fig. 5B) were Glu/tCr and tCho/tCr.
All individual metabolite ratios of importance for the sep-
arations between different groups were tested for their sta-
tistical significance using the paired t-test. As depicted in
Fig 2C, Tau/tCr was significantly decreased in ctx/hipp in
APP/PS1 mice during the four weeks of treatment (p =
0.019). However, there was no statistically significant dif-
ference for Gln/tCr after treatment in these mice. Moreo-
ver, for APP/PS1 mice a significant decrease in Tau/tCr (p
= 0.027) in str (Fig. 3C) was seen, which is in line with the
measurements from ctx/hipp. The metabolite ratio tCho/
tCr was significantly increased in str (Fig. 3D) in APP/PS1
mice (p = 0.019) after donepezil treatment. The metabo-
lite tCho/tCr was also significantly increased in str in the
untreated APP/PS1 mice (p = 0.001) (Fig. 4C). As can be
observed when comparing Fig. 3D and Fig. 4C the
increase in tCho/tCr is smaller in donepezil treated than
in untreated APP/PS1 mice. This was statistically verified
using a two-sample t-test (p = 0.011). The other metabo-
lite ratios of importance for the separation between
treated and untreated animals for APP/PS1 mice did not
reach statistical significance on an individual level. For wt
mice the only metabolite ratio reaching statistical signifi-
cance was Glu/tCr (p = 0.035) (Fig. 5C).
Acetylcholine-esterase (AchE) activity
To test the effect of donepezil as an acetylcholine-esterase
inhibitor, the brains of wt and tg mice were analyzed for
acetylcholine-esterase activity at the end of the treatment
(Table 2). There was a significant difference between
treated and non treated wt mice (p = 0.007). In the APP/
PS1 mice the mean activity in donepezil treated animals
was seemingly lower than the mean of animals receiving
NaCl injections; however it did not reach statistical signif-
icance.
Table 1: Mean metabolic ratios in each animal group before and after donepezil and NaCl respectively.
Mice type Brain region Treatment Gln/tCr Glu/tCr m-Ins/tCr Tau/tCr tCho/tCr tNAA/tCr
Mean ± SD
tg str before 0.64 ± 0.11 1.30 ± 0.13 0.96 ± 0.11 1.28 ± 0.10 0.33 ± 0.03 0.90 ± 0.13
tg str donepezil 0.77 ± 0.28 1.27 ± 0.34 0.89 ± 0.11 0.97 ± 0.23 0.38 ± 0.01 0.93 ± 0.15
tg str NaCl 0.59 ± 0.07 1.47 ± 0.22 0.97 ± 0.13 1.29 ± 0.14 0.39 ± 0.03 0.99 ± 0.07
tg ctx/hipp before 0.61 ± 0.13 1.48 ± 0.26 0.62 ± 0.15 0.86 ± 0.10 0.24 ± 0.03 1.19 ± 0.11
tg ctx/hipp donepezil 0.72 ± 0.08 1.60 ± 0.30 0.57 ± 0.07 0.73 ± 0.07 0.24 ± 0.03 1.24 ± 0.20
tg ctx/hipp NaCl 0.72 ± 0.17 1.60 ± 0.23 0.55 ± 0.14 0.85 ± 0.13 0.25 ± 0.04 1.18 ± 0.21
wt str before 0.61 ± 0.14 1.18 ± 0.12 0.78 ± 0.09 1.14 ± 0.10 0.34 ± 0.02 0.88 ± 0.10
wt str donepezil 0.67 ± 0.11 1.34 ± 0.16 0.79 ± 0.12 1.22 ± 0.13 0.36 ± 0.02 0.93 ± 0.05
wt str NaCl 0.72 ± 0.10 1.25 ± 0.11 0.78 ± 0.09 1.21 ± 0.13 0.34 ± 0.03 0.90 ± 0.06
wt ctx/hipp before 0.46 ± 0.16 1.37 ± 0.14 0.52 ± 0.08 0.78 ± 0.08 0.22 ± 0.02 0.96 ± 0.09
wt ctx/hipp donepezil 0.49 ± 0.09 1.34 ± 0.11 0.52 ± 0.06 0.75 ± 0.09 0.24 ± 0.03 0.99 ± 0.11
wt ctx/hipp NaCl 0.46 ± 0.06 1.41 ± 0.20 0.52 ± 0.09 0.77 ± 0.09 0.22 ± 0.02 1.03 ± 0.10
Abbreviations: Gln = Glutamine, Glu = Glutamate, Tau = Taurine, m-Ins= Myo-inositol, tCho = Choline-containing compounds, tNAA = N-
acetylaspartate+N-acetylaspartylglutamate, wt = wild type mice, tg = APP/PS1 transgenic mice, ctx/hipp = parietal cortex/hippocampus, str = 
striatum.BMC Neuroscience 2009, 10:33 http://www.biomedcentral.com/1471-2202/10/33
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MRS voxel placement and spectrum Figure 1
MRS voxel placement and spectrum. (A) Representative MRI featuring a frontal slice through a mouse brain with localiza-
tion 1.5 mm posterior to bregma in cortex/hippocampus. Placement of the voxel of interest (VOI) sized 4.0 × 1.6 × 1.6 mm3 
for spectroscopy as indicated by the white box. (B) Representative MRI featuring a frontal slice through a mouse brain with 
localization 0.5 mm anterior to bregma in striatum. Placement of the VOI sized 5.0 × 2.0 × 2.0 mm3 for spectroscopy as indi-
cated by the white box. (C) Representative wild type spectra from cortex/hippocampus to show the quality of spectra 
received. (D) Representative wild type spectra from striatum to show the quality of spectra received.
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Results from the data analysis of donepezil treated APP/PS1 (cortex/hippocampus) Figure 2
Results from the data analysis of donepezil treated APP/PS1 (cortex/hippocampus). (A) PLS-DA scatter plot which 
displays a clear separation between mice before and after donepezil treatment (white circles = before treatment and black cir-
cles after treatment). Each data point represents one mouse. A Q2-value above 0.05 indicates that the groups can be signifi-
cantly distinguished along that component. (B) Metabolites which are important for the separation between groups in the PLS-
DA model. VIP (variable of importance in the projection) values larger than 1 are relevant in explaining group differences (black 
bars) while metabolites with values below 1 have no significant impact (white bars). (C) The paired t-test shows a significant 
decrease in Tau, p = 0.019. White diamonds represent before treatment and black squares after treatment.
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Results from the data analysis of donepezil treated APP/PS1 (striatum) Figure 3
Results from the data analysis of donepezil treated APP/PS1 (striatum). (A) PLS-DA scatter plot which displays a 
clear separation between mice before and after donepezil treatment (white circles = before treatment and black circles after 
treatment). Each data point represents one mouse. A Q2-value above 0.05 indicates that the groups can be significantly distin-
guished along that component. (B) Metabolites which are important for the separation between groups in the PLS-DA model. 
VIP (variable of importance in the projection) values larger than 1 are relevant in explaining group differences (black bars) while 
metabolites with values below 1 have no significant impact (white bars). (C) The paired t-test shows a significant decrease in 
Tau, p = 0.027. White diamonds represents before treatment and black squares after treatment. (D) The paired t-test shows a 
significant increase in tCho, p = 0.019. White diamonds represent before treatment and black squares after treatment.
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Result from the data analysis of saline treated APP/PS1 (striatum) Figure 4
Result from the data analysis of saline treated APP/PS1 (striatum). (A) PLS-DA scatter plot which displays a clear 
separation between mice before and after saline treatment (white circles = before treatment and black circles after treatment). 
Each data point represents one mouse. A Q2-value above 0.05 indicates that the groups can be significantly distinguished along 
that component. (B) Metabolites which are important for the separation between groups in the PLS-DA model. VIP (variable of 
importance in the projection) values larger than 1 are relevant in explaining group differences (black bars) while metabolites 
with values below 1 have no significant impact (white bars). (C) The paired t-test shows a significant increase in tCho, p = 
0.001. White diamonds represent before treatment and black squares after treatment.
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Results from the data analysis of donepezil treated wild type mice (striatum) Figure 5
Results from the data analysis of donepezil treated wild type mice (striatum). (A) PLS-DA scatter plot which dis-
plays a clear separation between mice before and after donepezil treatment (white circles = before treatment and black circles 
after treatment). Each data point represents one mouse. A Q2-value above 0.05 indicates that the groups can be significantly 
distinguished along that component. (B) Metabolites which are important for the separation between groups in the PLS-DA 
model. VIP (variable of importance in the projection) values larger than 1 are relevant in explaining group differences (black 
bars) while metabolites with values below 1 have no significant impact (white bars). (C) The paired t-test shows a significant 
increase in Glu, p = 0.035. White diamonds represent before treatment and black squares after treatment.
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Discussion
Multivariate data analysis
We have demonstrated that by employing a combination
of 1H-MRS and multivariate data analysis, it is possible to
observe a treatment effect of donepezil in parietal cortex/
hippocampus and in striatum of APP/PS1 mice. We also
found a treatment effect in wt mice in str, but not in ctx/
hipp. Interestingly, the Tau/tCr ratio was decreased in str
and ctx/hipp of APP/PS1 mice due to donepezil treat-
ment. We also found a less pronounced increase in tCho/
tCr in str for treated APP/PS1 mice compared to untreated.
This shows that multivariate data analysis is a powerful
tool in analyzing complex biological data and that it is
possible to monitor treatment effects at an early stage. The
strength of multivariate data analysis compared to tradi-
tional univariate data analysis methods, such as the t-test,
is that it correlates the different metabolites to each other
and considers them all simultaneously. By doing so, it is
possible to observe patterns in the data not possible when
looking at the metabolites one by one.
The most significant separation between groups before
and after treatment was seen in str in APP/PS1 mice. A sig-
nificant separation, although less pronounced, was also
seen in ctx/hipp of APP/PS1 mice. Different density and
levels of expression of AchE in ctx/hipp and str may partly
explain this variance. In line with this, we saw a significant
separation between wt mice before and after treatment of
donepezil in str but not in ctx/hipp.
Tau/tCr decrease in donepezil treated APP/PS1 mice in 
parietal cortex/hippocampus and striatum
Tau is a free amino acid present in the brain. Areas in the
brain which contain the highest concentrations of Tau are
dorsal striatum and hippocampus [23]. This metabolite is
reported to be involved in a number of biological func-
tions. It acts as an organic osmolyte in the brain, involved
in cell volume regulation. Another role of taurine is mod-
ulation of the actions of neurotransmitters. The concen-
tration of Tau is much higher in rodent brains than in
human brains [24]. Dedeoglu et al showed an increase in
Tau in aged APP transgenic mice (age 20 months). Since
Tau plays a role in osmoregulation, similar to the role of
m-Ins in humans, this increase is suggested to reflect a
similar process to that which increased m-Ins plays in
human AD [24]. Marijanska et al showed an increase in
m-Ins in APP/PS1 mice (aged 20 months) and no increase
in Tau suggesting that this mouse model most closely
matches the neurochemical profile of human AD [22].
When we investigated APP/PS1 mice aged 2.5 to 9.0
months, we found no increase in Tau/tCr nor in m-Ins/tCr
in APP/PS1 mice [21]. Since no change of Tau/tCr in APP/
PS1 mice was detected within the first 9 months of life, the
observed decrease in Tau/tCr in the present study indi-
cates that it is a direct effect of donepezil treatment. This
is supported by the fact that the decrease in Tau/tCr was
observed in both ctx/hipp and str, which are both brain
regions with high concentrations of Tau. Also no effect on
Tau/tCr was seen in untreated APP/PS1 mice. Finally, no
decrease in Tau/tCr was seen in wt mice receiving donepe-
zil. It has previously been shown in rats that levels of the
amino-acid Tau are lowered following treatment with
another AchE inhibitor (ENA713) [25]. It was further sug-
gested that the AchE inhibitor, metrifonate has additional
properties which modulate other neurochemical systems
than the cholinergic [26].
The decrease in Tau may be directly connected to the
cholinergic activity, which is the target of many anti-AD
drugs. It has been shown that Tau inhibits the release of
Ach [27]. This suggests that lower levels of Tau lead to a
reduced inhibitory tone, resulting in increased cholinergic
activity [25].
Progressive increase in striatal tCho/Cr of APP/PS1 mice is 
partially mitigated by donepezil treatment
We observed a significant increase in striatal tCho/tCr of
APP/PS1 mice. However, this increase was significantly
lower in mice receiving donepezil compared to mice
receiving saline. We interpret the observed increase in the
levels of tCho/tCr in striatum of APP/PS1 mice to be an
effect of the disease process. This is in line with human
patient studies, where elevations in choline concentra-
tions have also been measured with MRS [2,28-30]. The
increase we observed is less pronounced in the animals
receiving donepezil treatment, which is in line with a
recent MRS study demonstrating a decrease in tCho levels
in probable AD patients treated with donepezil [9]. In this
study Bartha et al. suggest that the change in tCho they
observed in AD patients could reflect a decrease in phos-
phatidylcholine catabolism leading to lower levels of
tCho containing compounds, which are required precur-
sors for acetylcholine synthesis. The substances that
mainly contribute to the choline peak in a MRS spectrum
are free choline, glycerophosphocholine and phospho-
choline [28]. Choline is a precursor of acetylcholine and
it is also a product of membranial phosphatidylcholine
breakdown [1]. In AD there are losses of cholinergic neu-
rons and it was shown in vitro that levels of free choline
Table 2: AchE activity.
Mouse type n Treatment Mean ± SD
tg 5 donepezil 0.052 ± 0.005
tg 5 NaCl 0.056 ± 0.007
wt 10 donepezil 0.049 ± 0.005
wt 10 NaCl 0.056 ± 0.005
Abbreviations: wt = wild type mice, tg = APP/PS1BMC Neuroscience 2009, 10:33 http://www.biomedcentral.com/1471-2202/10/33
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and glycerophosphorylcholine are higher in AD brains
[31]. Moreover, higher levels of choline may be explained
by an increased cell membrane phospholipid turnover in
demented brains [28]
The target of donepezil is to inhibit the acetylcholine
breakdown by decreasing cholinesterase activity. Our
results are in full agreement with the studies discussed
above and they demonstrate a progressive increase in stri-
atal tCho/Cr, which is partially mitigated by donepezil
treatment in this mouse model of Alzheimer's disease.
Glu/tCr increase in donepezil treated wt mice in striatum
Glutamate is the most abundant neurotransmitter in the
brain. There is no specific theory on the role of glutamate
in AD. In general a decrease in glutamate is suggested to
be due to the death of glutamatergic cortical neurons and
an increase may reflect a potentially neurotoxic effect.
Glutamate also has a role in synaptic plasticity and
because of this it is believed that glutamic acid is involved
in learning and memory. We observed an increase in the
Glu/tCr ratio in the striatum of wt mice after donepezil
treatment. This finding is somewhat unexpected and at
present we have no plausible explanation. These changes
in glutamate might be connected to increased cholinergic
activity but we cannot rule out the possibility of direct
effects on glutamate levels from donepezil. Further studies
are required to investigate these findings.
Acetylcholine-esterase (AchE) activity
Donepezil significantly decreased the acetylcholine-este-
rase activity in wt mice, which might explain the increased
levels of Glu/tCr due to increased cholinergic activity.
However, donepezil did not significantly decrease the ace-
tylcholine-esterase activity in APP/PS1 mice. There are
several different explanations for this. One of the reasons
could be the small number of APP/PS1 mice tested com-
pared to wt mice. Another reason is the dose of donepezil
used. In order to confirm that the right dose was used, a
dose response study is warranted.
Conclusion
Treatment effects of the acetylcholine-esterase inhibitor,
donepezil can be detected in str and ctx/hipp of APP/PS1
mice by analyzing in vivo MRS data with multivariate data
analysis (PLS-DA). A disease dependent tCho/tCr increase
was observed in str of APP/PS1 mice. This increase was sig-
nificantly lower in APP/PS1 mice receiving donepezil,
which reflects a reversal of the levels of this metabolite
ratio. Moreover we found a decrease in Tau/tCr level in
both str and ctx/hipp s in APP/PS1 mice as a result of
donepezil treatment. Both the decrease in Tau/tCr and the
less pronounced increase in the tCho/tCr level might pos-
sibly be mediated by changed cholinergic activity as a
result of the donepezil treatment.
Methods
Experimental animals
23 female mice B6C3-Tg(APPswe, PSEN1dE9)85Dbo/
JTg/0 from The Jackson Laboratory (Bar Harbor, ME,
USA) and 20 female mice C57BL/6/Sca (wt) from Scanbur
BK, Denmark were used. The studies were approved by the
Northern Stockholm Ethics Committee on Experimental
Animal Care and performed in accordance with the guide-
lines from the Swedish National Board for Laboratory
Animals. Table 3 shows the different mouse groups, age,
number of animals, treatment and brain region used for
MRS.
Treatment
The mice were kept in a 12 h light/dark circle. Rodent
breeding diet R36 (Lactamin AB, Stockholm, Sweden) and
water were provided ad libitum. Donepezil (Eisai, Ibaraki,
Japan) was administrated i.p. daily for four weeks (0.6
mg/kg, i.p.) from postnatal week 12 to 16 or from 16 to
20. Mice not treated with Donepezil received i.p. saline
injection daily for four weeks (0.9% NaCl, i.p.). The mice
showed no sign of toxicity (i.e. no decreased locomotion,
drowsiness, or loss of weight).
Acetylcholine-esterase (AchE) activity assay
The protocol was adapted from [32,33]. Chemicals were
purchased from Sigma or Roth if not otherwise specified.
Frozen brain hemispheres were homogenized in a 1.5 mL
homogenization buffer (1 mM Sodiumhydrogencar-
bonate, 0.2 mM Magnesiumchloride, 0.2 mM Calcium-
chloride, 1 mM Spermidine, adjusted to pH 8.0). The
protein concentration was determined using the BCA
Table 3: Mice groups.
Mouse type n Age at beginning of treatment Treatment Investigated brain region
tg 6 12 weeks donepezil ctx/hipp
tg 7 12 weeks NaCl ctx/hipp
tg 5 16 weeks donepezil str
tg 5 16 weeks NaCl str
wt 10 12 weeks donepezil ctx/hipp and str
wt 10 12 weeks NaCl ctx/hipp and str
Abbreviations: wt = wild type mice, tg = APP/PS1transgenic mice, ctx/hipp = parietal cortex/hippocampus, str = striatum.BMC Neuroscience 2009, 10:33 http://www.biomedcentral.com/1471-2202/10/33
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assay (Pierce). Prior to the measurements, samples were
diluted 1:2 in the homogenization buffer and incubated
as described in the assay description. Measurements were
made using a TecanGenios ELISA reader (Tecan,
Crailsheim, Germany). Samples were then adjusted to 1
μg/μL protein contents using the homogenization buffer.
21 μL of the adjusted samples were then incubated in the
following buffers: a) 294 μL of 0.1 M Potassiumphos-
phate (pH 8.0); b) 21 μL DTNB solution (10 mM 5,5'-
Dithio-bis-2-nitro-benzoic acid in 0.1 MKPi pH 8.0
(titrated from 1 M potassiumphosphate and 1 M potassi-
umhydrogenphosphate) supplemented with 100 mg
sodiumhydrogencarbonate/100 mlKPi). The solution was
then gently mixed for 3 min. at room temperature and
finally 14 μL of the substrate 75 mM acetylthiocholine-
iodid (Fluka) was added to start the reaction. The primary
mix was substituted by 0.1 mM AchE inhibitor
BW284C51 for the negative controls. The measurements
were carried out in 60s time steps using the TecanGenios
ELISA Reader at 412 nm.
Animal preparation and anaesthesia
All mice were subjected to a MRI/1H-MRS investigation at
the beginning and the end of the 4 week donepezil or
saline treatment. The mice were anesthetized with 1.5–
2.0% isoflurane delivered through a face mask, allowing
for spontaneous respiration. The mouse was positioned in
supine position and the head fixed to the acrylic rig. Body
temperature was recorded and maintained at 36 to 37°C
using a MRI-compatible air temperature control system.
Respiratory rate was monitored continuously (BioTrigger,
Bruker, Karlsruhe, Germany).
MRI and 1H-MRS
MRI examinations were performed using a 4.7 T magnet
with a horizontal bore (Bruker Biospec Avance 47/40,
Bruker, Karlsruhe, Germany) equipped with a 12 cm inner
diameter self-shielded gradient system (max. gradient
strength 200 mTm-1). A commercially available volume
coil (Bruker, Karlsruhe, Germany) with an inner diameter
of 25 mm was used for excitation and signal detection.
Volumes of interest for spectroscopy were localized using
spin echo sequences with rapid acquisition with relaxa-
tion enhancement (RARE) imaging [34] producing either
a 3D volume with 64 × 64 phase steps covering the whole
brain or 2D slices in axial, coronal and sagital direction
consisting of 11, 7 or 9 continuous slices, respectively. The
parameters for 3-D inversion recovery were adjusted as
follows: repetition time (TR) 2566.8 ms, echo time (TE)
35.6 ms, RARE-factor 8 with RARE-maximum 4, inversion
time 450 ms, matrix size 64 × 64 × 128 and 2 averages.
The 3D volume measured 0.90 × 1.20 × 1.80 cm. The
parameters for the 2-D slices were adjusted as follows: TR
3000 ms, TE 37.4, RARE-factor 8 with RARE-maximum 4,
matrix size 256 × 256, slice thickness 1 mm, FOV 2.5 mm,
8 averages. The volume containing 11 consecutive 2D
slices in the axial direction was positioned with the first
slice at the rhinal fissure.
In this study single voxel 1H-MRS was performed in stria-
tum (str) and in parietal cortex/hippocampus (ctx/hipp)
in APP/PS1 and wild type (wt) mice. Braak and Braak
(1991) have described the progression of AD. It evidently
progresses from etorhinal cortex and hippocampus. The
pathology then continues to parietal cortex and frontal
cortex, before finally reaching the entire brain. We chose
to place the voxel of interest for the MRS experiment in
parietal cortex/hippocampus, due to the fact that AD
pathology starts there. Our MRS measurements in parietal
cortex/hippocampus showed effects on the brain metabo-
lite ratio taurine/creatine. Taurine is a metabolite which
can be found in high concentrations in striatum as well as
in hippocampus [23]. Therefore, we placed the second
MRS voxel in striatum. Great care was taken to position
the voxel in the same location for each animal. The voxels
were placed measuring from the rhinal fissure, where the
first 2D slice had been positioned to the pre-assigned VOI
location. The voxel in ctx/hipp (Figure 1A) was placed 1.5
mm posterior to bregma and 0.5 mm anterior to bregma
in str (Figure 1B). The VOI size was 4.0 × 1.6 × 1.6 mm
and represented a volume of 10.24 mm3 in ctx/hipp and
5.0 × 2.0 × 2.0 mm resulting in a volume of 20 mm3 in str.
A PRESS sequence with the following parameters was used
for MRS: TR 3500 ms, TE 20 ms, VAPOR water suppres-
sion [35], 512 averages in ctx/hipp and 256 averages in str.
The line width of the water peak was assessed in the VOI
before each MRS experiment to check the shim quality.
This was performed after adjusting the first order shims
using an unsuppressed water scan of 1 average. Resulting
line widths were between 12–18 Hz FWHM.
Quantification
The software package LCModel http://www.s-pro
vencher.com was used [36,37] for the analysis of the spec-
tra. The quantification algorithm of the LCModel applies
linear combinations to calculate the best fit of the experi-
mental spectra to the model spectra. The model spectra
were simulated to match the magnetic field strength, type
of sequence and sequence parameters used for the data
acquisition. The final analysis was performed in the fre-
quency domain with raw data (free induction decay
(FID)) as the input. In this study metabolic ratios are used
and no absolute concentrations. The ratios are given rela-
tive to creatine + phosphocreatine (tCr) as applied by oth-
ers [21,38,39]. The following 16 metabolites were
included in the basis set: alanine (Ala), aspartate (Asp),
creatine (Cr), γ-aminobutyric acid (GABA), glucose (Glc),
glutamate (Glu), glutamine (Gln), glycerophosphoryl-
choline (GPC), phosphorylcholine (PCho), myo-inositolBMC Neuroscience 2009, 10:33 http://www.biomedcentral.com/1471-2202/10/33
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(m-Ins), lactate (Lac), N-acetylaspartate (NAA), N-acety-
laspartylglutamate (NAAG), phosphocreatine (PCr),
scyllo-inositol, taurine (Tau). Also included are nine simu-
lated macromolecules and lipids.
Error estimates in the LCModel
In the LCModel the error in the quantification of different
metabolites is expressed in percent standard deviation.
These values represent the 95% confidence intervals of the
estimated concentration values. Table 4 shows the stand-
ard error estimates %SD (Cramér-Rao lower bounds,
CRLB) for the metabolites included in the analysis.
Metabolites which have a %SD >50% are considered to be
unreliable and can range from zero to twice the estimated
concentration. [40]. If the covariance between two metab-
olites was high, the sum of the two metabolites was
reported (Correlation coefficients >-0.5 and <0.5)
[21,41]. The metabolite ratios included in the study were:
glutamate (Glu/tCr), glutamine (Gln/tCr), myo-inositol
(m-Ins/tCr), taurine (Tau/tCr), choline-containing com-
pounds (tCho/tCr) and N-acetylaspartate+N-acetylaspar-
tylglutamate (tNAA/tCr).
Data analysis and statistics
The LCModel data was analyzed using Partial least square
discriminant analysis (PLS-DA), a supervised multivariate
data analysis method which is part of the SIMCA software
(Umetrics AB, Umea, Sweden). PLS-DA analyses were per-
formed using mean centring and unit variance scaling.
Mean centring improves the interpretability of the data,
by subtracting the average from the individual data for
each variable. Large variance variables are more likely to
be expressed in modelling than low variance variables.
Therefore, unit variance scaling was selected to scale the
data appropriately. This scaling method calculates the
standard deviation of each variable column. The inverse
standard deviation was used as a scaling weight and was
multiplied by each column. The results from the PLS-DA
analysis were visualized by plotting two components of
the model against each other. Each point in the scatter
plot represents one individual animal. Each component
receives a Q2 value that describes its statistical signifi-
cance. Q2 values > 0.05 are regarded as statistically signif-
icant. Q2 is the fraction of the total variation of the Y's that
can be predicted by a component according to cross vali-
dation (CV). CV means that a number of parallel models
are built. These models differ from each other by leaving
out a different individual from the total population each
time. The data of the left out animal is then predicted into
the respective model which produces a prediction value. A
prerequisite for PLS-DA is that two different groups are
compared. The prediction values from the two different
groups are for one group most correct if close to 1, while
for the other group most correct if close to 0. The cut off
value for accepting the observation as correctly predicted
is 0.5, or in other words <0.5 for one group and >0.5 for
the other group. From the respective CV predictions, the
sensitivity and specificity of the models can be calculated
as follows: Sensitivity, also called the "true positive rate"
is defined as the number of true positive predictions
divided by the sum of the number of true positive predic-
tions plus the number of false negative predictions. Spe-
cificity, also denominated "true negative rate" is defined
as the number of true negative predictions divided by the
sum of the number of true negative predictions plus the
number of false positive predictions.
Further we plotted variables according to their importance
for the separation of groups. All the variables received a
VIP (variable of importance in the projection) value. The
VIP values reflect the importance of the terms in the
model. VIP values larger than 1 suggest that the metabo-
lite is over average involved in the separation of groups.
Group differences for individual metabolites, also
denominated variables, were tested using the paired t-test.
Abbreviations
AchE: acetylcholine-esterase; AD: Alzheimer's Disease;
Ala: alanine; APP: β-amyloid precursor protein; Asp:
aspartate; Cr: creatine; CRLB: Cramér-Rao lower bounds;
ctx/hipp: fronto-parietal cortex and hippocampus; CV:
cross validation; GABA: γ-aminobutyric acid; Glc: glucose;
Gln: glutamine; Glu: glutamate; GPC: glycerophosphoryl-
choline;  1H-MRS: Proton magnetic resonance spectros-
copy; Lac: lactate; m-Ins: myo-inositol; NAA: N-
acetylaspartate; NAAG: N-acetylaspartylglutamate; PCho:
phosphorylcholine; PCr: phosphocreatine; PLS-DA: Par-
tial least square discriminant analysis; PS1: presenilin 1;
Table 4: Average Cramér-Rao lower bounds (CRLB) of measured metabolites (± SD).
Mice type Brain region Gln Glu Tau m-Ins tCho tNAA
tg ctx/hipp 33 ± 8% 11 ± 2% 21 ± 7% 16 ± 3% 13 ± 3% 9 ± 2%
tg str 23 ± 6% 11 ± 4% 11 ± 2% 9 ± 2% 6 ± 1% 8 ± 1%
wt ctx/hipp 32 ± 8% 9 ± 1% 15 ± 3% 12 ± 2% 9 ± 1% 7 ± 1%
wt str 20 ± 5% 9 ± 1% 9 ± 1% 7 ± 1% 5 ± 1% 7 ± 1%
Abbreviations: Gln = Glutamine, Glu = Glutamate, Tau = Taurine, m-Ins = Myo-inositol, tCho = Choline-containing compounds, tNAA = N-
acetylaspartate+N-acetylaspartylglutamate, wt = wild type mice, tg = APP/PS1 transgenic mice, ctx/hipp = parietal cortex/hippocampus, str = 
striatum, SD = standard deviation.BMC Neuroscience 2009, 10:33 http://www.biomedcentral.com/1471-2202/10/33
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RARE: rapid acquisition with relaxation enhancement; str:
striatum; Tau: taurine; tCr: creatine + phosphocreatine;
TE: echo time; tg: transgenic; TR: repetition time; VIP: var-
iable of importance in the projection; VOI: volumes of
interest; wt: wild type.
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